US regulatory status: approved.
pharma · Schizophrenia
Shanghai Mental Health
Shanghai Mental Health Center
Shanghai Mental Health drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Shanghai, CN HQ
1958 Founded
97 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Shanghai, CN
- Founded
- 1958
- Employees
- 97
- Programs
- 1
- Drugs
- 2
- Patents
- 0
Shanghai Mental Health pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Shanghai Mental Health drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
olanzapine
Nervous system (N05)US regulatory status: approved. Molecular target: D2-like dopamine receptor.
- Target
- D2-like dopamine receptor
- Mechanism
- D2-like dopamine receptor antagonist